One of the major challenges in cancer gene therapy is the identification of functionally relevant tumor-specific genes as the therapeutic targets. MicroRNAs (miRNAs) are a class of small, 22-25 nucleotides, endogenously expressed noncoding RNA. miRNAs are important genetic regulators: one miRNA can possibly target multiple genes and they can function as tumor promoters (oncogenic miRNAs, oncomirs) or tumor suppressors (anti-oncomirs). Therefore, the identification of misregulated miRNAs in cellular signaling pathways related to oncogenesis can have profound implications for cancer therapy. The epithelial-mesenchymal transition (EMT) converts epithelial cells into mesenchymal cells, a normal embryological process that frequently get activated during cancer invasion and metastasis. Recent evidence also supports the presence of a small subset of self-renewing, stem-like cells within the tumor mass that possess the capacity to seed new tumors and they have been termed 'cancer stem cells (CSC)'. Conceivably, these CSCs could provide a resource for cells that cause therapy resistance. Although the cell origin of CSCs remains to be fully elucidated, a growing body of evidence has demonstrated that the biology of EMT and CSCs is tightly linked with the sequences and compositions of miRNA molecules. Therefore, targeting miRNAs involved in EMT and CSCs regulation can provide novel miRNA-based therapeutic strategies in oncology.
INTRODUCTION
Besides overcoming many of the technical hurdles involved in the delivery of therapeutic genes into target cells of patients, successful gene therapy strategies depend heavily on the identification of relevant molecular targets, genes that may aid in the management or correction of a disease. Recent research has shown that there is a complex microRNA (miRNA) network that functions as regulators of molecular targets that drive the transformation of human cancers. In this review, we have summarized the molecular entities and roles of miRNAs in human cancers, including the miRNAs that target and regulate epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) hoping to promote the development of these as novel miRNA-based anticancer therapeutics.
miRNAs are a class of small, 22-25 nucleotides, endogenously expressed noncoding RNA. The first 'miRNA', lin-4, was identified in 1993, 1,2 whereas the second 'miRNA', let-7, was reported in 2000 in Caenorhabditis elegans. 3 However, it was in 2001 that the term miRNAs was introduced to designate this class of endogenously expressed noncoding short single-stranded RNAs. 4, 5 Since then, the miRNA field has been explored extensively and at last count, there are 1527 precursors and 1921 mature human miRNAs registered in the Sanger miRBase v18 (http://www. microrna.sanger.ac.uk/registry/; the Wellcome Trust Sanger Institute). In humans, miRNA genes are located in all chromosomes, with the exception of the Y chromosome. 6 miRNAs modulate post-transcriptional gene regulation by binding to complementary sequences in the 3'-untranslated regulatory regions (3 0 -UTR) causing the degradation of target mRNAs and thereby preventing translation. As their binding to the complementary 3 0 -UTR need not be perfect, these mismatches allow one miRNA to possibly target multiple genes involved in different cellular signaling pathways related to oncogenesis. Furthermore, some miRNAs can function as tumor promoters or as tumor suppressors depending on particular cell type and pattern of gene expression. Therefore, miRNAs are important genetic regulators and the identification of misregulated miRNAs in cellular transformation and maintenance of the malignant state can have profound implications for cancer therapy.
ONCOGENIC miRNAs (ONCOMIRS) AND TUMOR SUPPRESSOR miRNAs (TS-miRs)
In this review, we focus on the molecular roles of miRNA in human cancers and we have summarized the numerous examples of oncogenic and tumor-suppressive miRNAs that are frequently implicated in human cancers (Table 1) .
The first report to implicate the link between miRNAs and cancer was in 2002. Calin et al. 7 identified that miR-15 and miR-16 were causally involved in the pathogenesis of chronic lymphocytic leukemia. The discovery that some miRNAs can function as tumor promoters or as tumor suppressors to repress oncogenes in healthy cells have led to new insights into molecular pathways involved in oncogenesis. MiR-17-92 represents the first example of an oncogenic and TS-miRs. In physiologic conditions, the miR-17-92 cluster can limit MYC activation by dampening the E2F positive feedback loop. In tumors with MYC activation, the miR-17-92 cluster protects cells from MYC-induced apoptotic E2F responses, leading to uncontrolled cellular proliferation. 8, 9, 10 This realization has resulted in a quest to understand the pathways that are regulated by these miRNAs and to comprehend the feasibility of targeting oncogenic miRNAs and restoring tumor-suppressive miRNAs for cancer therapy.
Deregulation of miRNAs expression through genomic amplification, chromosomal deletions, point mutations and aberrant promoter methylation emerges as the main mechanism that triggers their loss or gain of function in human cancers. Although aberrantly expressed miRNAs could potentially act as good cancer biomarkers, the identification of functional-relevant 'driver' miRNAs with cancer-associated phenotypes, such as cell proliferation and cell invasion might yield crucial targets for novel cancer therapy. For examples, the tumor suppressor BRCA1 has been shown to epigenetically represses miR-155 expression via its association with histone deacetylase 2, which deacetylates histones H2A and H3 on the miR-155 promoter. As a consequence, overexpression of miR-155 accelerates whereas knockdown of miR-155 attenuates the growth of tumor cells. As inactivating germline BRCA1 mutations are present in approximately 40% of families with multiple cases of breast cancer and it is known that most tumors with BRCA1 mutation also show high expression of miRNA-155, thus suggesting that miR-155 is a potential therapeutic target for BRCA1-deficient tumors. 11 The aberrant expression of miR-21 is closely associated with cell proliferation, antiapoptosis, migration, invasion and metastasis in various cancers, including breast cancer. Expression of miR-21 was found to be elevated in grade 2 and 3 as compared with grade 1 invasive ductal carcinoma. It was demonstrated that miR-21 can downregulate the expression of tumor suppressor genes such as tropomyosin 1, programmed cell death 4 and the phosphatase and tensin homolog. [12] [13] [14] Similarly, many TS-miRs have been shown to be often downregulated or lost in human cancers. 15 For example, the human let-7 family contains 13 members located on nine different chromosomes, and many human cancers have deregulated let-7 expression. For some forms of cancer, most or all let-7 family members appear to be downregulated while the downregulation of specific family members in various cancers has also been described. 16 Hence, the loss of let-7 family members could provide prognostic value as it indicates poor survival in lung cancer, whereas the specific downregulation of let-7d (combined with low miR-205 expression) was predictive of poor survival in head and neck squamous cell carcinoma patients. 16 It was also determined that human let-7 can specifically target RAS, c-Myc and HMGA2, which is a chromatin-associated nonhistone protein capable of modulating chromatin architecture and thus affecting transcription. 16 miR-143 and miR-145 are transcribed from a putative cluster on chromosome 5 and they are coordinately expressed in a variety of cell types and tissues. They are frequently downregulated in a broad range of cancer cell lines and tumors deriving from the haematopoietic system, breast, lung, colon, prostate, the gastrointestinal system, ovary, cervix, head and neck, and bladder tissue. In colorectal cancer (CRC), miR-143 targets KRAS mRNA to influence CRC cell proliferation and survival and miR-145 directly inhibits the translation of YES and STAT1 mRNA. 17 Hence, restoration of TS-miRs expression is a potentially useful therapeutic option in cancers where its expression has been lost.
miRNAs IN EMT TRANSITION AND CANCER METASTASIS
Tumor metastasis is one of the most serious challenges for managing human cancers as the majority of cancer mortality is associated with disseminated disease, rather than the primary tumor. Recently, the discovery of miRNAs having very important Up to 90% of all human cancers are carcinomas, which are cell growths that originate in epithelium. Epithelial cells are closely adjoined by specialized membrane structures, such as tight junctions, adherens junctions, desmosomes and gap junctions and hence, cells do not detach and move away from the epithelial layer under normal conditions. In contrast, cultured mesenchymal cells do not form an organized cell layer and they contact neighboring mesenchymal cells only focally and tend to be highly motile. The EMT converts epithelial cells into mesenchymal cells, a normal embryological process that is frequently implicated in cancer aggressiveness and metastasis. 38 Morphologically, EMT is characterized by a loss of cell adhesion and increased cell motility. At a molecular level, it is characterized by the decreased expression of the cell adhesion molecule and epithelial marker, E-cadherin, and the increased expression of the intermediate filament protein and mesenchymal cell marker, Vimentin. EMT allows benign tumors to progress into metastatic cancers that can invade other tissues. 39 The evaluation and comparison of miRNAs in human cancers and EMT can provide insights into the type of miRNAs that regulate EMT to drive the transformation of tumor. In Table 2 , we have summarized the EMT-associated miRNAs that have been identified and their target genes in various cancer types.
EMTs are transdifferentiation programs that are required for tissue morphogenesis during embryonic development. 79 Many of the miRNA targets listed in Table 2 are transcription factors critically involved in the control of EMT, including Snail homolog 1, ZEB1/2, TWIST1 and Slug. Snail has been associated with gastrulation, the earliest EMT within the developing embryo. The expression of Snail in the epiblast acts to repress E-cadherin, claudins and occludin directly, which promote the disassociation of epithelial cells to allow subsequent migration through the primitive streak. 80 Induction of EMT in cancer cells results in the acquisition of invasive and metastatic properties. Hence, targeting miRNAs involved in regulating EMT pathways can be a promising therapeutic strategy. 82 Despite their potential clinical significance, how intrinsic CSC properties are regulated at the molecular level is poorly understood. miRNAs have been linked to control the self-renewal and differentiation of embryonic stem cells and emerging evidence indicates that miRNAs may also regulate CSC properties. Differences in miRNA expression and disparity in the molecular pathways between cancer cells and CSCs have been demonstrated. miRNAs that have been implicated in various human cancers are summarized in Table 3 . Targeting these miRNAs may provide potentially new strategies for specific and efficient therapies for CSCs. high /CD24 low and were able to form mammospheres. Subsequently, the connection of EMT and CSCs was demonstrated in many other human cancers. We have also previously showed that miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling in human nasopharyngeal carcinoma. 115 In Table 4 , we have summarized the miRNAs that are important in EMT and CSCs. Linking EMT and CSCs to specific miRNAs will enable us to better understand how metastatic cancer arisen while targeting these regulatory miRNAs may provide new ways to strike cancer at its root.
miRNAs REGULATION OF CSCs
Recent studies of neoplastic tissues have provided evidence of self-renewal, stem-like cells within tumors that have been called CSCs, capable of both tumor initiation and sustaining tumor growth. CSCs are cells within a tumor mass that possess the capacity to self-renew and maintain tumor-initiating capacity through differentiation into the heterogeneous lineages of cancer cells that comprise the whole tumor. 81 These tumor-initiating cells could also provide the resource for cells that cause tumor recurrence and drug resistance. CSCs have very different properties from the bulk of the tumor, as they divide much more slowly and have very efficient drug-resistance mechanisms.
TRANSLATING miRNAs AS NOVEL TARGETS FOR CANCER THERAPEUTICS
High-throughput functional genomic studies have enabled pathway-based cancer treatment strategies to be formulated. Unfortunately, despite substantial progress in understanding cancersignaling networks, effective pathway-based therapies remain scarce due to insufficient disruption of many oncogenic pathways. The discovery that one miRNA can possibly target multiple genes involved in different cellular signaling pathways relating to oncogenesis makes miRNAs attractive targets for molecular cancer therapy. Exploiting expression profiling of miRNAs to reveal differential gene expression between tumor and normal tissues would enable the formulation of effective differentiation expressionbased transcriptional regulatory cancer therapeutic strategies. There are two strategies to develop miRNA-based therapies, blocking oncogenic miRNAs and restoring tumor-suppressive miRNAs (Figure 1 ). Current strategies to block oncogenic miRNAs include anti-miRNA oligonucleotides, miRNA sponges, miRNA masks (target protectors) and small molecule inhibitors. 125 The anti-miRNA antisense oligonucleotides specifically bind and inhibit endogenously expressed oncomirs. To increase the stability and binding affinity, many modifications to the chemical structure of the oligonucleotides have been developed, including the introduction of 2 0 -O-methyl groups or locked nucleic acid (LNA). These constructs display remarkably increased thermodynamic stability and enhanced nucleic acid recognition. Krutzfeldt et al. 126 first reported that 2 0 -O-methyl-modified cholesterol-conjugated single-stranded RNA analogs, termed 'antagomirs', were efficient and specific silencers of endogenous miRNAs in mice. LNA is a modified RNA nucleotide in which the ribose ring is 'locked' by a methylene bridge connecting the 2 0 -O atom and the 4 0 -C atom. LNA nucleotides can be mixed with DNA or RNA residues in the oligonucleotide to increase the sensitivity and specificity. Elmé n et al. 127 showed that an LNA-modified oligonucleotide (LNA-anti-miR-122) effectively antagonized the liver-expressed miR-122 in non-human primates. The Santaris Pharma A/S clinically developed this LNA-based drug called miravirsen. As of late 2010, miravirsen is in a phase 2 study in patients infected with Hepatitis C (http://clinicaltrials.gov). Miravirsen is a host-targeted, pan-HCV genotype antiviral agent and the first miRNA-targeted drug to enter clinical trials. Unlike Hepatitis C therapies that directly target the virus, miravirsen works by removing a 'helper' molecule (miR-122) that the virus needs in order to make new Abbreviations: CSC, cancer stem cell; EMT, epithelial-to-mesenchymal transition; SIRT1, silent mating type information regulation 2 homolog 1; Vim, vimentin; ZEB1/2: zinc-finger E-box-binding homeobox 1 or 2.
Connecting miRNA, EMT and CSC for cancer therapy H Xia et al copies. miRNA sponges are synthetic mRNA containing multiple tandem-binding sites to the endogenous miRNA of interest and are being transcribed from mammalian expression vectors to prevent interactions between miRNA and the endogenous targets. The sponge can be stably expressed in mammalian cells and as with most miRNA target genes, a sponge's binding sites are specific to the miRNA seed region, which allows them to block a whole family of related miRNAs. 128 This transgenic approach has proven to be a useful tool to probe miRNA functions in a variety of experimental systems. 129 On the other hand, the miRNA-mask approach results in enhanced gene expression by removing the repressive effects of a particular miRNA on protein translation of the target mRNA. This method tests whether a target is regulated by an miRNA and interrogates the physiological role of this regulation in vivo. miRNA masks consist of single-stranded 2 0 -Omethyl-modified antisense oligonucleotides that are fully complementary to predicted miRNA binding sites in the 3 0 -UTR of the target mRNA. This technology has recently been validated by Choi et al. 130 in a zebrafish model to prevent the repressive actions of miR-430 in transforming growth factor-b signaling pathways and provided insight into the role of miR-430 in targeting the morphogen nodal and the chemokine signal SDF-1a (stromal-derived factor-1 alpha). From the perspective of their secondary structures, miRNAs appear to be 'druggable.' 131 The formation of stem loops found in pre-miRNAs and the bulges in miRNAs facilitate targeting by small molecules. Gumireddy et al., 132 after screening more than 1000 compounds and carrying out structure-activity relationship analyses, identified diazobenzene and its derivatives as effective inhibitors of pri-miR-21 formation, demonstrating the feasibility of this approach.
The loss of tumor-suppressive miRNAs enhances the expression of target oncogenes. Therefore, delivery of miRNAs that are highly expressed and therefore tolerated in normal tissues but lost in cancer cells may provide a general strategy for highly specific miRNA-based therapies. There are strategies developed to restore tumor-suppressive miRNAs in human cancers, including synthetic miRNA precursor or miRNA mimics (Figure 1) . 133 For example, miR26a, a miRNA that is normally expressed at high levels in diverse tissues. Kota et al. expressed this miRNA in liver cancer cells in vitro to induce cell cycle arrest. Furthermore, these authors demonstrated that systemic administration of miR-26a in a mouse model of human hepatocellular carcinoma using adeno-associated virus miR-26a to target cyclins D2 and E2 resulted in the inhibition of cancer cell proliferation, induction of tumor-specific apoptosis and dramatic protection from disease progression without toxicity. 134 Given the relevance of miRNAs, EMT and CSCs in cancer development and progression, the challenges become how miRNAs regulate EMT and CSCs and whether targeting miRNAs involved in regulating EMT and CSCs could offer potential novel therapeutic strategies in oncology. In this review, we have summarized the currently available information on the differential expression of miRNAs in human cancers in particularly the miRNAs listed in Table 4 have been demonstrated to be tightly associated with both EMT phenotypes and maintenance of CSCs. They are good candidates for designing next-generation miRNAbased cancer therapeutics targeting EMT and CSCs. But a few words of caution in the midst of this optimism; although many of the miRNAs were first discovered and well studied in C. elegans, little is known about their function in normal mammalian development and physiology. Understanding the biology of miRNA in the regulation of EMT and CSCs and developing efficient and flexible in vivo delivery systems for miRNAs would greatly enhance the development of clinically meaningful therapeutic strategies. 
